Bid opening of the second round of centralized purchase! The price of acarbose is as low as 10% with a decrease of 80% - 90%

Wen Jie Linan On January 17, the second round of centralized procurement bidding, which attracted the attention of the industry, was under way in Shanghai Pharmaceutical Institute A total of 33 varieties were collected, covering the treatment fields of diabetes, hypertension, anti-tumor and rare diseases According to on-site media reports, 122 enterprises participated in the bidding The purchasing base of this time is 12.4 billion pieces (bags / piece), and the agreed purchasing volume of each variety is 50-80% of the purchasing base According to the associated press of finance, some enterprises, such as Sanofi's glimepiride, gave up their offers even though they arrived at the site The final results will be officially released three days after the announcement, and patients from all over the country can use the selected drugs in April Among the 25 varieties selected in the first round of national centralized collection, the average decline rate was 52%, and the maximum decline rate was 96% In the second round of the first round (4 + 7 expansion), the average decrease of 4 + 7 was 25%, and atorvastatin, the largest one, was reduced by 78.18% on the basis of 4 + 7 bidding price From the current outflow of varieties, the overall decline of this round of centralized mining is expected to be larger than the previous two times In fact, this result is not expected in the industry Shi lichen, founder of Beijing Dingchen medical management consulting center, said that the price reduction of drugs in the second round of centralized purchase bid opening will be greater than that in the first round, because the negotiation ability of national negotiators has been further improved after the last round In addition, the rules have changed, mainly reflected in the expansion from exclusive bid winning to six bid winning enterprises The more shortlisted enterprises, the greater the drop in drug prices In addition, in this centralized purchase, Shanghai has released the purchase volume needed by each province, and implemented the real volume purchase at the objective level It can be seen that the country has better negotiation elements at the systematic level, which is reflected in price negotiation, entry rules, quantity, planned procurement quantity of each province, implementation cycle differentiation, regional selection priority, disciplinary rules, etc Nowadays, the state intends to normalize and scale the centralized procurement In addition to the nationwide centralized procurement organized by the National Health Insurance Bureau, various local governments are also experimenting with various forms of belt procurement, such as recently carrying out belt procurement for urban and rural residents with hypertension and diabetes in Hebei Province; carrying out special belt procurement for insulin in Wuhan; taking the lead in carrying out belt procurement for antibacterial drugs in Hunan Province; Fujian Province has no more than one in 14 Conduct on-line purchasing of drugs for risk assessment Before that, Hebei two disease drug collection was called as the prelude to the second round of belt quantity purchase by the industry insiders There are 13 varieties of two disease collection in Hebei Province, among which acarbose and glimepiride are the same as the shortlisted varieties in the national collection The shortlisted enterprises of acarbose tablet (50mg) in the public results of Hebei Province are Hangzhou, Central America and East China, with a median price of 0.61 yuan / tablet, compared with the previous one in East China The standard price decreased by 59.1%, 70.6% compared with the original research Bayer; the shortlisted enterprise of glimepiride tablet (2mg) was Beijing Beilu, and the price of the selected tablets was 0.2618 yuan / tablet, with a decrease of 80.75% It is worth noting that the highest price of Acarbose Tablets (50mg) and glimepiride tablets (2mg) in the second round of centralized purchase is 0.8353 yuan and 0.3 yuan respectively The prices of these two drugs in Hebei Province are all below this, and the emergence of the lowest price in China has a great impact on the second round of centralized purchase Previously, it was predicted that there were 4 competing enterprises of Acarbose Tablets (50mg) in this round of centralized mining, including original research Bayer, Sichuan LVYE, Hangzhou Zhongmei Huadong, Beijing Fuyuan, and 7 competing enterprises of glimepiride tablets (2mg), including original research Sanofi, as well as domestic pharmaceutical enterprises such as Guizhou shengjitang, Beijing Beilu, Chongqing kangkel, Shandong Xinhua, Jiangsu Wanbang biochemical pharmaceutical group Hairui Pharmaceutical Co., Ltd., Guangzhou, Yangtze River In the second round of centralized drug purchase, the media learned that in this round of centralized drug purchase, acarbose's bidding enterprises included Huadong pharmaceutical's subsidiaries Zhongmei Huadong, LVYE pharmaceutical and Bayer, with the prices of 13.96 yuan, 9.6 yuan and 5.42 yuan respectively, and the specifications of 50mg / 30 tablets Bayer's single conversion price is 0.1807 yuan, which is nearly 80% lower than the maximum effective bidding price According to the rules of the shortlist, up to two of the three declared enterprises may be shortlisted, and China, the United States and East China may face a direct exit Bayer offered a lower price than Hebei's shortlisted enterprises in China, the United States and East China, with fierce competition In the bidding of glimepiride tablets (1mg), Sanofi, the original research group, gave up the offer, and Chongqing kangkeri pharmaceutical gave the offer of 0.053 yuan / tablet In addition, although the results of glimepiride tablets (2mg) are not available, the reduction is not expected to be too low compared with the quotation of comcel In tadalafei's bidding, Jiangsu Tianshili and Changchun Haiyue won the bid with 42.4 and 47.0304, and Qilu, Nanjing Tianqing and Lilai were out; in addition, as the only injection product in the collection, Hengrui, Shiyao, Qilu and Xinji, the bidding enterprises of albumin paclitaxel, offered 780, 747, 1828 and 1150 yuan / piece respectively, and Qilu was out In addition, the three products of olmesartan ester, moxifloxacin and fordostan won the bid From the perspective of quotation, the single calculation quotation of these three varieties is 85%, 90% and 70% lower than the highest effective bidding price; among the bidding products of tegio, Hengrui and Qilu won the bidding successfully.